Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Sangamo Expand Zinc Finger Tech License

NEW YORK (GenomeWeb News) – Sigma-Aldrich and Sangamo BioSciences today announced an expansion of their licensing deal covering zinc finger DNA binding protein-modified cell lines.

Under the new pact, Sigma-Aldrich gains exclusive rights to develop and distribute the ZFP-modified cell lines for commercial production of protein pharmaceuticals. In addition, Sigma-Aldrich has rights to certain ZFP-engineered transgenic animals for commercial applications.

"The zinc finger technology platform developed by Sangamo is a core component of Sigma-Aldrich's growth strategy into high-value biologic tools," Sigma-Aldrich Chairman, President, and CEO Jai Nagarkatti said in a statement. "Expanding our capability to provide ZFN-modified cells for the commercial production of therapeutic proteins and vaccines takes us into markets with enormous commercial potential, and we fully intend to maximize the value of these assets."

Financial terms of the agreement were not disclosed.

Filed under

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.